Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) and Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Profitability
This table compares Intellia Therapeutics and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intellia Therapeutics | -805.75% | -64.74% | -50.72% |
| Ionis Pharmaceuticals | -56.98% | -120.62% | -16.99% |
Earnings and Valuation
This table compares Intellia Therapeutics and Ionis Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Intellia Therapeutics | $67.67 million | 20.82 | -$412.69 million | ($3.35) | -3.00 |
| Ionis Pharmaceuticals | $944.00 million | 4.69 | -$381.39 million | ($3.32) | -8.01 |
Ionis Pharmaceuticals has higher revenue and earnings than Intellia Therapeutics. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Intellia Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intellia Therapeutics | 4 | 7 | 9 | 1 | 2.33 |
| Ionis Pharmaceuticals | 1 | 3 | 19 | 0 | 2.78 |
Intellia Therapeutics currently has a consensus target price of $21.44, indicating a potential upside of 113.61%. Ionis Pharmaceuticals has a consensus target price of $75.00, indicating a potential upside of 182.14%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Intellia Therapeutics.
Volatility & Risk
Intellia Therapeutics has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.
Summary
Ionis Pharmaceuticals beats Intellia Therapeutics on 9 of the 14 factors compared between the two stocks.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
